WC
VKTX icon

Woodstock Corp’s Viking Therapeutics VKTX Stock Holding History

Woodstock Corp’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-73,151
Closed -$426K – 204
2020
Q3 		$426K Hold
73,151
– – 0.07% 123
2020
Q2 		$527K Hold
73,151
– – 0.09% 114
2020
Q1 		$342K Hold
73,151
– – 0.07% 123
2019
Q4 		$587K Buy
73,151
+18,188
+33% +$133K 0.1% 112
2019
Q3 		$378K Buy
54,963
+200
+0.4% +$1.49K 0.07% 129
2019
Q2 		$455K Hold
54,763
– – 0.08% 126
2019
Q1 		$544K Buy
+54,763
New +$458K 0.1% 117

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Woodstock Corp's VKTX Position: Q4 2020 in Review

Woodstock Corp sold out of Viking Therapeutics (VKTX) in Q4 2020, closing a stake of 73,151 shares — an estimated $426K sold.

Woodstock Corp first reported a position in VKTX in Q1 2019 and held it in 7 quarters. The position peaked at $587K in Q4 2019. 143 funds tracked by Wall St. Rank hold VKTX as of Q4 2020.

  • Woodstock Corp reported no remaining Viking Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Woodstock Corp sold 73,151 Viking Therapeutics shares in Q4 2020, an estimated $426K.
  • Woodstock Corp first reported a position in Viking Therapeutics in Q1 2019 and held it in 7 quarters.
  • Woodstock Corp's Viking Therapeutics position peaked at $587K in Q4 2019.
  • 143 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2020.

Based on Woodstock Corp's 13F filing for Q4 2020, filed 6 Jan 2021.